Dynamics of Adrenal Steroids Are Related to Variations in Th1 and Treg Populations during Mycobacterium tuberculosis Infection in HIV Positive Persons by Quiroga, Maria Florencia et al.
Dynamics of Adrenal Steroids Are Related to Variations
in Th1 and Treg Populations during Mycobacterium
tuberculosis Infection in HIV Positive Persons
Maria Florencia Quiroga
1*, Matias Tomas Angerami
1, Natalia Santucci
2, Diego Ameri
3,4, Jose Luis
Francos
5, Jorge Wallach
5, Omar Sued
3,4¤, Pedro Cahn
3,4, Horacio Salomo ´n
1, Oscar Bottasso
2
1Department of Microbiology, National Reference Center for AIDS, University of Buenos Aires School of Medicine, Buenos Aires, Argentina, 2Institute of Immunology,
University of Rosario School of Medical Sciences, Rosario, Argentina, 3Infectious Diseases Unit, J.A. Ferna ´ndez Hospital, Buenos Aires, Argentina, 4Huesped Foundation,
Buenos Aires, Argentina, 521 Unit, F.J. Mun ˜iz Infectious Diseases Hospital, Buenos Aires, Argentina
Abstract
Tuberculosis (TB) remains the most frequent cause of illness and death from an infectious agent, and its interaction with HIV
has devastating effects. We determined plasma levels of dehydroepiandrosterone (DHEA), its circulating form DHEA-
suphate (DHEA-s) and cortisol in different stages of M. tuberculosis infection, and explored their role on the Th1 and Treg
populations during different scenarios of HIV-TB coinfection, including the immune reconstitution inflammatory syndrome
(IRIS), a condition related to antiretroviral treatment. DHEA levels were diminished in HIV-TB and HIV-TB IRIS patients
compared to healthy donors (HD), HIV+ individuals and HIV+ individuals with latent TB (HIV-LTB), whereas
dehydroepiandrosterone sulfate (DHEA-s) levels were markedly diminished in HIV-TB IRIS individuals. HIV-TB and IRIS
patients presented a cortisol/DHEA ratio significantly higher than HIV+, HIV-LTB and HD individuals. A positive correlation
was observed between DHEA-s and CD4 count among HIV-TB individuals. Conversely, cortisol plasma level inversely
correlated with CD4 count within HIV-TB individuals. M. tuberculosis-specific Th1 lymphocyte count was increased after
culturing PBMC from HIV-TB individuals in presence of DHEA. We observed an inverse correlation between DHEA-s plasma
level and Treg frequency in co-infected individuals, and CD4+FoxP3+ Treg frequency was increased in HIV-TB and IRIS
patients compared to other groups. Strikingly, we observed a prominent CD4+CD25-FoxP3+ population across HIV-TB and
HIV-TB IRIS patients, which frequency correlated with DHEA plasma level. Finally, DHEA treatment negatively regulated
FoxP3 expression without altering Treg frequency in co-infected patients. These data suggest an enhancing role for DHEA in
the immune response against M. tuberculosis during HIV-TB coinfection and IRIS.
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Introduction
Tuberculosis continues to be the most successful pathogen
around the world, and its interaction with HIV fuels both
epidemics [1]. Infection largely takes place in the lungs and most
newly infected persons experience a favourable course of these
lesions with the caseating necrotic material being encapsulated by
concentric layers of epithelioid cells, lymphocytes and some giant
cells. In a few cases granulomas may evolve unsatisfactorily with
softening of the caseum and presence of very high numbers of
bacilli which are expelled through the bronchus or spread via the
hematogenous route. Post-primary TB can result in distinct
clinical outcomes starting with asymptomatic latent infection,
through mild forms of disease, to progressive disease with
important necrosis and cavity formation [2]. The great majority
of TB cases result from reactivation of old lesions, likely due to the
presence of predisposing factors such as malnutrition, steroid
therapy or concomitant diseases, i.e., diabetes, leukaemia or HIV
infection [3,4]. Tuberculosis and HIV are two chronic infectious
diseases capable of influencing each other throughout several
immune-dysregulated processes. For example, HIV infection alters
the immune response to mycobacteria, notably Mycobacterium
tuberculosis, with significant morbidity and mortality in HIV-
positive patients. The introduction of the highly active antiretro-
viral therapy (HAART) to treat HIV infection resulted in the
restoration of the immune system an improvement of immunity
against HIV and other pathogens [5]. In some HIV-infected
patients the restoration of pathogen-specific immune responses
during the initial months of highly active antiretroviral treatment
(HAART) could elicit immunopathological inflammatory respons-
es, leading to the development of immune reconstitution
inflammatory syndrome (IRIS). The prevalence of IRIS among
HIV patients starting HAART ranges from 3 to 31.7% and
includes viral, fungal, parasitic and bacterial diseases [6]. In the
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clinical deterioration during specific antibiotic therapy), or as
unmasking TB IRIS (a clinical manifestations of latent TB
infection). Mycobacteria account for approximately 40% of all
cases of infectious IRIS in patients initiated on HAART [7,8]. The
frequency of paradoxical TB-IRIS range from 8% to 43% whereas
the occurrence of unmasking TB IRIS is more restricted [6]. As
occurs in most infectious diseases, clinical manifestations of TB
and IRIS is the result of a complex series of interactions between
pathogens and immune response [6].
The demonstration of an increase in the number of purified
protein derivative-specific Th1 IFN-c-producing T cells and Th1
cytokines in IRIS patients [9] and a study in Africa employing
several mycobacterial antigens [10] point out a role of Th1 cells as
being implied on IRIS phenomenon. Moreover, the relevance of
Th1 responses in tuberculosis has been very well described.
Recently, it has been demonstrated for the first time that IFN-c
combined with vitamin D are able to kill M. tuberculosis inside
infected human macrophages, showing the relevance of endocrine
modulation on anti-mycobacterial immune responses [11].
Besides the intrinsic immunomodulatory influences account-
ing for disease occurrence, factors like steroid hormones are
likely to play a role in this regard. In fact, inflammatory
cytokines produced during tuberculosis, i.e., IFN-c,T N F - a and
IL-6 can also activate the hypothalamic-pituitary-adrenal (HPA)
axis leading to the final production of steroid hormones by the
adrenal with well known influences on the immune response
[12]. As an example, glucocorticoids (GC) can promote a Th2
cytokine acquisition profile [13], facilitating Th2 activities,
whereas its natural antagonist dehydroepiandrosterone -DHEA-
is able to favour Th1 cytokine production and interfere with
Th2 cytokine synthesis [14]. DHEA and its sulfated prohor-
mone, DHEA sulfate (DHEA-s) are quantitatively the most
abundant circulating adrenal steroid hormones in humans.
C i r c u l a t i n gD H E A - ss e r v e sa sar e s e r v o i rf o rD H E A ,w i t h
conversion by sulfotransferases occurring in a wide range of
tissues. There is also extensive metabolism to estrogens and
androgens, giving rise to the view that many of its effects are
mediated by these hormones or other metabolites like andros-
tenediol and androstenetriol [15]. Whereas DHEA-s is the
hydrophilic storage form that circulates in the blood, only
lipophilic DHEA can be converted intracellularly to androgens
and estrogens. Thus, the tissue-specific synthesis of DHEA
sulfotransferase and steroid sulfatase determines the ratio of
DHEA activation (by conversion to sex steroids) to transient
DHEA inactivation (by secretion of the sulfate ester back into
the bloodstream) [15,16]. Working in conjunction, all these
factors may modify the nature of the specific immune response
that underlies the spectrum of clinical manifestations during
HIV-TB infections. Regarding the utilization of DHEA and/or
DHEA derivatives in the treatment of tuberculosis, it has been
shown that the synthetic adrenal steroid derivative 16 a-
bromoepiandrosterone (EpiBr; 16 a-bromo-5a -androstan-3b-
ol-17-one), exerted beneficial effects in clinical and experimental
tuberculosis and HIV patients [17,18,19].
Regulatory T cells (Treg) play a central role in the prevention of
autoimmunity and in the control of immune responses by down-
regulating the function of effector CD4(+) or CD8(+) T cells.
Moreover, Treg are central for maintaining the balance between
immune-mediated suppression of M. tuberculosis and immunopa-
thology in patients with tuberculosis [20,21]. Given the role of
Treg in the maintenance of immune homeostasis quantitative or
functional defects in these cells may be also involved in TB-IRIS
[22].
Within this setting our study sought to investigate the immuno-
endocrine interactions occurring during different clinical scenarios
of HIV-TB co-infection as an attempt to get a better understand-
ing of the disease physiopathology. Specifically we aimed to
explore the role of adrenal hormones in the modulation of the
frequency of M. tuberculosis - specific Th1 lymphocytes and Treg
during co-infection with HIV and TB and also during the course
of IRIS. We hypothesize that cell frequency will be influenced by
cortisol and DHEA, modulating both innate and adaptive immune
responses to M. tuberculosis.
Materials and Methods
Patients and study design
The present study has a cross-sectional design in which patients
were included prospectively during a 3-year period. Five groups of
individuals were enrolled: 1) Asymptomatic HIV-1 infected
patients (HIV+, n=10, male: 6, female: 4), as determined by
ELISA and confirmatory Western Blot who were tuberculin skin
test negative (TST
neg); 2) HIV-1 infected patients with active TB,
who received less than one week of anti-TB therapy also TST
neg
(HIV-TB, n=21, male: 17, female: 4); 3) HIV-TB individuals with
TB-IRIS (for simplicity, denoted as IRIS patients from now on,
n=6, male: 4, female: 2); 4) HIV-1 infected individuals latently
infected with M. tuberculosis (HIV-LTB, n=5, male: 2, female: 3) as
determined by TST and 5) Bacillus Calmette-Guerin-vaccinated
healthy donors TST
neg (HD, n=16, male: 8, female: 8). No
patient received DHEA and/or glucocorticoid treatment. Com-
parisons by sex yielded no differences in the immune-endocrine
variables under analysis. Patients were evaluated at Hospital J.A.
Ferna ´ndez and Hospital F.J. Mun ˜iz, Buenos Aires, Argentina.
Diagnosis of TB was based on the identification of acid-fast bacilli
in sputum, or a positive culture of tuberculosis bacilli and clinical
and/or radiological data. All HIV individuals were under
antiretroviral treatment following current guidelines [23]. HIV
and HIV-TB patients had no evidence of IRIS development. IRIS
was diagnosed following the criteria proposed by International
Network for the Study of HIV-associated IRIS [10]. All IRIS cases
were first diagnosed as having TB and afterwards initiated HIV
treatment; therefore diagnosed as paradoxical TB. Written
informed consent was obtained, according to the local Ethics
Committee. The characteristics of all participants are shown in
Table 1.
Hormone assessments
In order to assess cortisol, DHEA and DHEA-s plasma levels
EDTA-anticoagulated blood samples were drawn. After centrifu-
gation, plasma aliquots were preserved at -80uC. Cortisol was
measured by electrochemiluminescence (automatic analyser AD-
VIA CentaurH XP Immunoassay System, Siemens Healthcare
Diagnostics, Deerfield, IL, USA), DHEA by radioimmunoassay
(Packard Cobra II Gamma Counter, Packard, Meriden, CT,
USA) and DHEA-s by immunochemoluminiscence (IMMULI-
TEH 1000, Siemens Healthcare Diagnostics, Deerfield, IL, USA)
tests. All hormone determinations were performed in the same
blood samples collected between 8:00 and 8:30 a.m. because of the
circadian rhythms.
Antigen
In vitro stimulation of cells was performed with pre-titrated heat-
killed M. tuberculosis H37Rv (Mycobacteria Research Laboratories,
Colorado State University, Fort Collins, CO) at 10 mg/ml final
concentration for all the experiments prepared by probe
sonication.
Modulation of TB Immune Response by DHEA in HIV
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e33061ELISPOT assays
IFN-c-secreting cells were detected using enzyme-linked
immunospot (ELISPOT) assays conducted as described previously
[24]. Briefly, peripheral blood mononuclear cells (PBMC) were
cryopreserved as described elsewhere [24], and 1 day before the
assay, they were thawed and rested overnight in RPMI medium
supplemented with 10% fetal bovine serum (Gibco BRL), 2 mM
Lglutamine (Gibco BRL), 100 U/ml penicillin (Gibco BRL),
100 mg/ml streptomycin (Gibco BRL), and 10 mM HEPES
(Gibco BRL) and viability was checked by trypan blue exclusion,
as described [24]. Rested PBMCs were plated on sterile 96-well
plates (MultiScreen IP plates; Millipore), previously coated with
mouse anti-human IFN-c monoclonal antibody (BD Biosciences)
at 10
5 cells/well. Heat-killed M. tuberculosis strain H37Rv was
added in duplicate wells (final concentration, 10 mg/ml). Stimu-
lating dose of M. tuberculosis antigen was determined by titration
using PBMC from healthy volunteers stimulated in vitro. Cortisol or
DHEA (both from Sigma-Aldrich) were added at different
physiological concentrations of DHEA (10
27 M, 10
28 M) and a
slightly supraphysiological concentration of cortisol (10
26 M).
Negative (medium plus 0.05% DMSO) and positive (PMA 5 ng/
ml plus Ionomicin, 500 ng/ml, both from Sigma-Aldrich) controls
were included for each patient. Plates were developed using
biotinylated anti-human IFN-c monoclonal antibody, streptavidin-
peroxidase complex, and AEC (3-amino-9-ethylcarbazole) sub-
strate reagent set (BD Biosciences). Plates were scanned on an
ImmunoSpot reader (Cellular Technology Ltd.). Specific spots
were counted using the ImmunoSpot software. Results were
expressed as spot forming units (SFU)/10
6 PBMC after subtrac-
tion of the negative-control values.
Culture conditions
PBMC were isolated by density gradient centrifugation on
Ficoll-Paque and cultured at 1610
6 cells/ml with M. tuberculosis
(10 mg/ml) in 24 or 96-well plates with RPMI medium
supplemented with 10% fetal bovine serum (Gibco BRL), 2 mM
Lglutamine (Gibco BRL), 100 U/ml penicillin (Gibco BRL),
100 mg/ml streptomycin (Gibco BRL), and 10 mM HEPES
(Gibco BRL) in the presence or absence of cortisol and DHEA
(both from Sigma-Aldrich) at the indicated concentrations. After
3 days, cells were harvested, and Treg frequency was determined
by flow cytometry.
Treg determination
Freshly isolated PBMC or cultured cells were stained with anti-
CD4 PerCP, anti-CD25 FITC (BD Biosciences) for 15 min at 4uC
in the dark. Subsequently, they were fixed and permeabilized with
the Human FoxP3 Buffer Set (BD Biosciences) following the
manufacturer’s instructions, before intracellular staining with PE-
conjugated FoxP3 (259D/C7, BD Biosciences) for 30 min. For
flow cytometric analysis, lymphocytes were gated on CD4
+
lymphocytes, and afterwards the percentages of CD25
+ and/or
FoxP3
+ cells was determined.
Statistical analysis
Statistical analysis was performed using the non-parametric
Wilcoxon matched pairs test for paired samples, and the Kruskall-
Wallis analysis of variance, followed by post hoc comparisons
(Dunns test) when applicable for between-groups comparisons.
Correlations were determined using Spearman’s rank test.
Analyses were performed using Prism v 5.01software (GraphPad
Software Inc., La Jolla, CA, USA). A p value , 0.05 was
considered statistically significant.
Results
Hormone levels and IFN-c responses along the spectrum
of HIV-TB coinfection
In order to determine an association of DHEA, DHEA-s and
cortisol levels with HIV-TB, IRIS, HIV+ or HIV-LTB conditions,
we initially assessed adrenal hormone levels in plasma from
patients and healthy donors (HD). Previously, we observed a
profound decrease in DHEA levels in TB patients, in parallel to an
increase in cortisol [25], We observed that DHEA plasma levels
were significantly diminished in HIV-TB and IRIS patients
compared to HD, HIV-LTB and HIV+ individuals (p,0.05),
whereas DHEA-s levels were markedly diminished in HIV-TB
with IRIS individuals (p,0.01 compared to HD, Fig. 1A y 1B).
Furthermore, cortisol values were similar among groups except for
HIV+ persons, whose cortisol levels were significantly lower
compared to HIV-TB patients (p,0.05, Fig. 1C). When analyzing
the cortisol/DHEA ratio, co-infected patients and IRIS patients
presented a cortisol/DHEA ratio significantly higher than HIV+,
HIV-LTB and HD individuals (p,0.001, p,0.05, p,0.05
respectively, Fig. 1D), with HIV+ and HIV-LTB patients
displaying slightly but still statistically significant lower cortisol/
DHEA ratio than HD (p,0.01 and p,0.05 respectively, Fig. 1D).
Continuing our studies, we wished to investigate the relationship
between immune status and adrenal hormone levels during HIV
and tuberculosis co-infection, we performed correlation analyses
between DHEA-s or cortisol levels and CD4
+ T cell counts. A
positive correlation was observed between DHEA-s and CD4
counts among HIV-TB individuals (rs=0.450195, p=0.0406,
n=21), but also when grouping all the individuals regardless their
Table 1. Epidemiological characteristics of the subjects enrolled.
Active TB Latent TB IRIS HIV HD
n 21 n 5 n 6 n 10 n 16
Median age in years (IQR) 35 (32 – 45) 36 (29 – 47) 31.5 (30 – 34) 37 (33.5 – 41) 39 (22 – 42)
Female/male distribution 4/17 3/2 2/4 4/6 8/8
HIV status (positive over total) 21 (100%) 5 (100%) 6 (100%) 10 (100%) 0 (0%)
Median CD4 count (IQR) 53 (25.4 – 887) 541(505 – 576) 199.8 (54.41 – 255.1) 433.5 (189 – 588.8) 769 (602 – 887)
Median Viral Load (IQR) 78999 (986.5 – 389992) 138 (65 – 21777) 380,5 (187.8 – 1146) 71,5 (50 – 1377) N/A
BCG vaccinated (positive over total) 21 (100%) 5 (100%) 6 (100%) 10 (100%) 16 (100%)
BCG, Bacillus Calmette-Guerin. IQR, Interquartile range.
doi:10.1371/journal.pone.0033061.t001
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plasma levels correlated inversely with CD4 counts within HIV-
TB individuals (rs=-0.5160, p=0.0237, n=21), and all the
enrolled individuals (rs=-0.3869, p=0.0066, n=44).
Since DHEA has the potential to induce Th1 responses [25,26],
we aimed to investigate the role of adrenal hormones on the IFN-c
responses to M. tuberculosis in co-infected patients. First, we aimed
to define each group’s antigen-specific responses by ELISPOT
assays and observed an increased frequency of IFN-c producing
cells in IRIS patients compared to HIV, co-infected, latently co-
infected and HD individuals (Fig. 2A).
When studying the effect of adrenal hormones on the IFN-c
responses from HIV-TB co-infected individuals, we observed that
cortisol treatment decreased the frequency of cytokine-producing
cells, and this effect could not be reverted by DHEA addition
(Fig. 2B). Notably, DHEA treatment could significantly enhance
the IFN-c responses to the antigen in co-infected patients (Fig. 2B).
Moreover, IRIS patients displayed the same trend as co-infected
patients, but without significance, likely due to the lower sample
size (data not shown). Finally, no enhancing effect of DHEA on
IFN-c was seen when studying cultures from HIV
+ individuals,
HIV-LTB patients or HD (data not shown).
FoxP3
+ T cell and FoxP3
+ CD25
- T cell frequencies are
increased and correlate with adrenal hormone plasma
level in co-infected and IRIS patients
The frequency of Treg (defined as CD25
+ FoxP3
+ regulatory
CD4 T cells) was reported to be higher both in HIV and
tuberculosis infections [27,28]. Moreover, a role for Treg in IRIS
development has been proposed [22]. Nevertheless, during co-
infection there are no clear data available on Treg regarding their
frequency and function. Adrenal hormones have been proposed to
regulate the expression of the FoxP3 gene [29], therefore having a
role in regulating immune responses. Initially, we performed
correlation analyses in order to investigate the role of adrenal
hormones on the frequency of Treg in the context of HIV-TB co-
infection. We observed an inverse correlation between DHEA-s
plasma levels and Treg frequency (rs=-0.5073, p=0.0114, n=24)
in infected individuals.
When assessing CD4+ CD25+ FoxP3+ Treg frequency, we
observed similar percentages among groups, except the HIV-LTB
group that showed lower values, statistically significant in relation
to HIV-TB patients (Fig. 3A and D). Strikingly, we observed the
emergence of a prominent population of Treg lacking CD25
expression among co-infected and IRIS patients (Fig. 3B and D),
significantly higher than HIV
+, HIV-LTB individuals and HD.
When analyzing total FoxP3
+ expression in CD4 T cells
irrespective of CD25 expression, we observed the same differences
among groups (Fig. 3C and D). We thoroughly studied Treg
populations within each group, and observed higher significant
proportions of FoxP3
+ CD25
- Treg compared to FoxP3
+ CD25
+
in HIV-TB and IRIS patients (Fig. 4A and B), whereas HIV, HIV-
LTB individuals and HD showed significantly increased percent-
ages of FoxP3
+ CD25
+ Treg compared to FoxP3
+ CD25
- cells
(Fig. 4C, D and E). Moreover, the frequency of these
‘‘unconventional’’ FoxP3
+ CD25
- Treg cell negatively correlated
with DHEA-s plasma levels (Fig. 5F, rs=-0.6473, p=0.0006,
Figure 1. Cortisol, dehidroepindrosterone-sulfate (DHEA-s), DHEA levels and Cortisol/DHEA ratio in HIV, HIV-TB, IRIS, HIV-LTB and
HD. A. DHEA, B. DHEA-s, C. Cortisol and D. Cortisol/DHEA (ratio) levels in plasma of HIV+, HIV-TB, IRIS, HIV-LTB, and HD individuals. Bars indicate the
mean 6 SEM for each group. Horizontal lines indicate comparisons between groups and statistically significant differences. DHEA was measured by
radioimmunoassay, DHEA-s by immunochemoluminiscence tests and Cortisol by electrochemiluminescence. HIV+ individuals n=10, HIV-TB n=21,
IRIS n=6, HIV-LTB n=5, and HD n=16. *: p , 0.05; **: p , 0.01; ***: p , 0.001.
doi:10.1371/journal.pone.0033061.g001
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PBMC from HIV-TB individuals in the presence of media, with
no variation in FoxP3 expression in the CD25 negative population
being observed (data not shown).
Finally, we wanted to investigate the role of DHEA on the
expression of FoxP3 and the percentage of Treg in co-infected
patients. Adding DHEA failed to cause any difference from values
seen in cells cultured with control media in either the percentage
of FoxP3
+ CD25
+ cells or intensity of Foxp3
+ in those cells (data
not shown). M. tuberculosis stimulation induced a significant
increase of FoxP3
+ CD25
+ Treg frequency only in co-infected
patients (Fig. 5A) without modifying Treg percentage in healthy
donors (Fig. 5B). In both groups, the addition of DHEA resulted in
no change in the percentage of Treg cells induced by the antigen.
In contrast,, in vitro treatment with DHEA significantly diminished
FoxP3 expression in FoxP3
+ CD25
+ Treg from co-infected
patients after culture with M. tuberculosis Ag (Fig. 5C and E),
without modifying Treg frequency (Fig. 5A and E). On the other
hand, culture of PBMC from healthy donors in the presence of
DHEA could not modulate the expression of FoxP3 nor the
frequency of Treg in response to M. tuberculosis stimulation (Fig. 5B,
D and E).
Discussion
People infected with M. tuberculosis and HIV exhibit a higher risk
to developing progressive diseases from both pathogens. The
complex bi-directional interaction between them turns out to
favour a M. tuberculosis-mediated stimulation of HIV-1 replication,
and on the other hand HIV infection exerts detrimental effects on
the course of TB. Such scenario is further complicated by the
appearance of IRIS during HAART leading to a strong recovery
of CD4 T cell responses, which may promote an overt TB or
exacerbate a previously established disease.
Data about immuno-endocrine disturbances during HIV-TB
co-infection are scarce and our paper provides several pieces of
new information about the relationship between the HPA, in
terms of adrenal steroids, and the immune response mounted by
patients undergoing both infections. Extending previous findings
on HIV patients [30] our study demonstrates that DHEA levels
are reduced in HIV-TB and HIV-TB-IRIS, the latter group also
showing lower amounts of DHEA-s. Reduced levels of DHEA
may be the result of a persistent immuno-inflammatory response
in both groups of patients. This is in line with a previous report
showing the inhibitory effects of culture supernatants from Ag-
stimulated PBMC from TB patients on in vitro DHEA production
by adrenal cells [12]. The same is likely to apply for the lower
amounts of DHEA-s seen in IRIS patients, although some changes
in the conversion of DHEA-s into DHEA may be also involved. In
this sense, inflammation-related compounds are known to affect
DHEA sulphate metabolism [31] and HIV-TB-IRIS is character-
ized by an increased inflammatory response [32].
Further support for a relative deficiency of the HPA axis during
HIV infection is provided by cortisol measurements. In fact, our
results showed that HIV patients had rather diminished cortisol
levels and HIV-TB and IRIS patients presented modestly
increased amounts of this steroid but statistically insignificant in
relation to HD. As a result, both groups depicted an increased
cortisol/DHEA ratio which may be inefficient for the control of
inflammatory reactions, since the slightly increased cortisol levels
would not compensate for the anti-inflammatory effect of DHEA
[14], because its levels were markedly reduced. Since cortisol is
involved with the stress response, whereas DHEA deals with the
stress adaptation, the imbalance seen in both groups may reflect a
more unfavorable stressful condition which may further impact on
the immune responses developed by them.
Our results also expand the knowledge of regulatory influences
of adrenal steroids on the immune response. Production of GCs
during infections mediates not only anti-inflammatory effects but
also favors an immune response that seems to be unsuitable to
clear intracellular pathogens [33,34,35]. The negative correlation
between cortisol levels and CD4 counts in HIV-TB individuals
and the inhibitory effects of this hormone on IFN-c production in
the same group of patients is in line with such statement. In
contrast, DHEA augmented IFN-c production in the same group
of patients which in turn corroborates its Th1 favoring effects [14].
Dissimilar findings were seen when analyzing correlations. In
fact, DHEA correlated positively with CD4 count from HIV-TB
patients and the whole population sample, whereas a negative
association between DHEA levels and frequency of Treg was
found in the former group. This result fits well with the
demonstration that DHEA inhibited FoxP3 expression in HIV-
TB patients; a finding that provides novel information about the
mechanisms by which DHEA modulates the immune response.
In tuberculosis, the potentially protective Th1 cell response may
result in an immunopathological response that fails to eliminate
the bacteria [36]. Within this setting control mechanisms like those
Figure 2. Modulation of M. tuberculosis-induced IFN-c produc-
tion by adrenal hormones. A. Absolute numbers of IFN-c producer
cells from PBMC of HIV+, HIV-TB, IRIS, HIV-LTB and HD patients, which
have been stimulated with M. tuberculosis antigen for 16 hours.
Horizontal lines indicate the mean and comparisons between groups
and statistically significant differences are shown. SFU, Spots forming
units. B. Percentage of IFN-c producer cells relative to M. tuberculosis in
PBMC of HIV-TB patients (n=12). PBMC (10
5 cells/well) were stimulated
in the presence of M. tuberculosis with or without addition of DHEA
and/or cortisol at the indicated concentrations. Each bar illustrates the
mean 6 SEM of the percentage for IFN-c producer cells relative to M.
tuberculosis for the each group, calculated as follows: % of IFN-c relative
to Mtb=([(Mtb hormone-Media)-(Mtb-Media)]/(Mtb-Media))6100. Aster-
isks indicate comparisons between each condition against Mtb specific
response. *: p , 0.05; **: p , 0.01.
doi:10.1371/journal.pone.0033061.g002
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PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e33061Figure 3. Analysis of Treg population across the spectrum of TB infection. Percentage of Treg cell populations (A. CD4+FoxP3+CD25+ Treg,
B. CD4+FoxP3+CD25- Treg and C. CD4+FoxP3+ Treg) of HIV-TB (n=11), HIV+ (n=7), HIV-LTB (n=4), IRIS (n=5) and HD (n=10) individuals. D.
Representative data for Treg flow cytometric analysis from HIV-TB (upper left), IRIS (upper center), HIV (upper right), HIV-LTB (lower left) and HD
(lower right) individuals. The plots shown were gated first on lymphocytes by scattering properties, then on CD4+ T cells and finally analyzed for
expression of CD25 and FoxP3. A, B and C. For the box and whisker plots, the horizontal line represents the median, the boxes represent the
interquartile range and the whiskers represent the minimum and maximum values. Asterisks indicate comparisons between groups. *: p , 0.05; **: p
, 0.01; ***: p , 0.001.
doi:10.1371/journal.pone.0033061.g003
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damage without interfering with processes involved in pathogen
clearance [37]. In our series, Treg were only affected in HIV-LTB
patients who showed decreased numbers; the implications on
whether it represents a different immuno-inflammatory situation
affecting both the differentiation and activity of Treg should be
analyzed in future studies.
As regards FoxP3, its expression was augmented in HIV-TB
and HIV-TB-IRIS patients, particularly in Mtb-stimulated CD25+
cells from HIV-TB patients. The transcription factor Foxp3 was
originally identified as a master regulator of thymus-derived
natural Treg (nTreg) and constitutes the most reliable marker to
specify these subsets [37]. Because Foxp3 expression in these Treg
is critical for the maintenance of Treg-specific functions [38], it
may be assumed that HIV-TB and HIV-TB-IRIS patients have an
increased Treg activity likely addressed to ameliorate the
accompanying immuno-inflammatory response that usually takes
place in these kind of patients. Instead of that, an expansion of
Figure 4. Expanded ‘‘non-conventional’’ Treg in HIV-TB and IRIS patients. Analysis of CD4+FoxP3+CD25+ and CD4+FoxP3+CD25-
populations within Treg in A; HIV-TB (n=11), B; IRIS (n=5), C; HIV-LTB (n=4), D; HD (n=10) and E; HIV (n=7) individuals. Horizontal lines inside the
boxes indicate the means 6 SEM of each group. Asterisks denote comparisons between each sub-population. *: p , 0.05; **: p , 0.01; ***: p, 0.001.
F. Spearman correlation analysis between plasma DHEA and the percentage of CD4+FoxP3+CD25- lymphocytes from all grouped patients (HIV+, HIV-
TB, IRIS, HIV-LTB and HD). Results of statistical analysis are shown in the graphic.
doi:10.1371/journal.pone.0033061.g004
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PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e33061Treg with a concomitant reduced functional capacity of suppressor
cells and diminished IL-10 secretion has been demonstrated in
IRIS patients [22], suggesting an underlying defect in these cells,
perhaps due to a decreased FoxP3 expression. Other studies in
HIV negative individuals with lung TB underline the potential role
of Treg since increased frequencies of both total CD4+CD25+ T
cells and CD4+ CD25
high cells were shown during active disease,
preferably in the involved lung [39,40]. In the same sense, a higher
percentage of circulating CD4+CD25
high T cells together with
increased levels of FoxP3 mRNA in PBMC from TB patients was
found, even higher at sites of active inflammation and tissue
pathology [41].
In line with the general features of the IRIS, HIV-TB-IRIS
patients had a higher IFN-c production, which among its many
activities is known to be essential for the control of M. tuberculosis
infection [25]. Remarkably, these patients as well as those with
HIV-TB also displayed increased levels of FoxP3+ CD25- cells,
with reduced numbers of this cell population being found in HIV,
HIV-LTB and HD groups. This intriguing cell population is
increased in systemic lupus erythematosus patients [42], being its
nature under discussion since some authors suggested that these T
cells were mostly FoxP3+ CD25- non-Treg [43], whereas others
have proposed that these cells were dysfunctional Treg which
suppressed T cell proliferation but not IFN-c production in vitro
[44]. FoxP3 expressed by Treg is relatively stable whereas that of
non-Treg is not [43,45]. Therefore, taking into account our
observations on the stability of FoxP3, we believe that these cells
are dysfunctional Treg. On the other hand, a recent report
described a CD25
low FoxP3+ GITR+ Treg population in
peripheral blood from HD with a strong suppressive activity on
T cell proliferation, although the authors didn’t investigate the
ability of these cells to inhibit cytokine secretion [46]. Overall, we
propose the analysis of these ‘‘unconventional’’ regulatory T cells
in HIV-TB co-infection as an interesting issue for future research
in the area of tuberculosis pathogenesis in the context of HIV
infection.
As recorded in the case of conventional Treg, DHEA
concentrations correlated negatively with FoxP3+ CD25- cells.
Adrenal hormones modulate the expression of FoxP3 and the
frequency of Treg in an autoimmune setting [47,48]. Thus, we
hypothesize that in co-infected patients the increased cortisol to
DHEA ratio could upregulate the expression of FoxP3 and
therefore the generation of dysfunctional Treg lymphocytes. Our
in vitro observations support the idea of a negative regulation of the
FoxP3 transcription factor by DHEA, which was also seen in cells
from Addison’s disease patients [48].
The HPA axis is a major constituent of the neuroendocrine
system. Once the magnitude of the defensive response to a
microbial agent becomes relevant, activation of the HPA axis
follows with significant influences on the immune function [49].
Our results associate adrenal steroids with critical components of
the immune response against HIV and M. tuberculosis, and provide
a stimulating background for studying more about these links, both
for a deeper comprehension of pathogenic mechanisms and the
potential development of adjuvant interventions.
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